natgillin/translations-raw huggingface dataset:
Your doctor will monitor you regularly while you are receiving Baraclude. 
Med zdravljenjem z zdravilom Baraclude boste pod rednim zdravniškim nadzorom.
The film-coated tablets (tablets) are white to off-white and triangular-shaped. 
Izgled zdravila Baraclude in vsebina pakiranja Filmsko obložene tablete (tablete) so bele do sivobele barve in trikotne oblike.
Baraclude 0.5 mg film-coated tablets 
Baraclude 0,5 mg filmsko obložene tablete
Each ml of oral solution contains 0.05 mg entecavir. 
NAVEDBA ENE ALI VEČ UČINKOVIN Vsak ml vsebuje 0,05 mg entekavirja.
Marketing Authorisation Holder and Manufacturer 
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet z zdravilom:
Oral solution Clear, colourless to pale yellow solution 
Peroralna raztopina je bistra, brezbarvna do bledorumena raztopina.
Baraclude 1 mg film-coated tablets entecavir 
Baraclude 1 mg filmsko obložene tablete entekavir
(Year 1), after week 58 through week 102 (Year 2), after week 102 through week 156 (Year 3), after week 156 through week 204 (Year 4), or after week 204 through week 252 (Year 5). 
Vključuje bolnike z vsaj eno določitvijo HBV DNA s PCR, v 24. tednu zdravljenja ali kasneje do 58. tedna (1. leto), med 58. tednom in 102. tednom (2. leto), med 102. tednom in 156. tednom (3. leto), med 156. tednom in 204. tednom (4. leto) ali med 204. tednom in 252. tednom (5. leto).
Proportion undetectable (<300 copies/ml)b 49%* Mean change from baseline (log10 copies/ml)c 
Delež nedokazljivih (<300 kopij/ml)b
The oral solution should be used for patients with body weight less than 32.6 kg. Paediatric patients with body weight at least 32.6 kg, should be administered 10 ml (0.5 mg) of the oral solution or one 0.5 mg tablet once daily. 
Pediatrični bolniki s telesno maso vsaj 32,6 kg morajo jemati 10 ml (0,5 mg) peroralne raztopine ali eno 0,5 mg tableto enkrat na dan.
30 x 1 film-coated tablet; 3 blister cards of 10 x 1 film-coated tablet each in Alu/Alu perforated unit dose blisters, or 
30 x 1 filmsko obloženo tableto v 3 perforiranih enoodmernih pretisnih omotih (Alu/Alu), ali 90 x 1 filmsko obloženo tableto v 9 perforiranih enoodmernih pretisnih omotih (Alu/Alu).
In studies in nucleoside-naive patients, 6% of entecavir-treated patients and 10% of lamivudine-treated patients experienced ALT elevations (> 10 times ULN and > 2 times reference [minimum of baseline or last end-of-dosing measurement]) during post-treatment follow-up. 
V študijah pri bolnikih, ki se še niso zdravili z nukleozidi, so se med spremljanjem po zdravljenju vrednosti ALT povečale (za > 10 krat od ULN in > 2 krat od referenčne vrednosti [najmanjše ob izhodišču ali zadnje, izmerjene ob prekinitvi zdravljenja]) pri 6% bolnikov, ki so se zdravili z entekavirjem in 10% bolnikov, ki so se zdravili z lamivudinom.
Baraclude 0.05 mg/ml oral solution 
IME ZDRAVILA Baraclude 0,05 mg/ml peroralna raztopina
0.15 mg once daily OR 0.5 mg every 72 hours 
0,5 mg vsakih 72 ur
Therefore, virological response should be closely monitored. 
Ker njihova varnost in učinkovitost nista bili klinično ovrednoteni, je treba virusni odziv skrbno nadzirati.
* for doses < 0.5 mg Baraclude oral solution is recommended. 
0,5 mg vsakih 72 ur * za odmerke < 0,5 mg priporočamo uporabo Baraclude peroralne raztopine.
Dizziness, tiredness (fatigue) and sleepiness (somnolence) are common side effects which may impair your ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Sposobnost vožnje in upravljanja strojev lahko zmanjšajo omotica, utrujenost in zaspanost (somnolenca), ki so pogosti neželeni učinki.
Bristol-Myers Squibb A.E. 
Bristol-Myers Squibb B.V.
Recommended Once Daily Dose of Oral Solutionb 
Priporočeni odmerek peroralne raztopine enkrat na danb
Severe Managed with Haemodialysis 
Zdravljenje s hemodializo
Baraclude 0.5 mg film-coated tablets entecavir 
Baraclude 0,5 mg filmsko obložene tablete entekavir
Talk to your doctor or pharmacist before taking Baraclude if you have ever had problems with your kidneys, tell your doctor. 
Pred začetkom jemanja zdravila Baraclude se posvetujte s svojim zdravnikom ali s farmacevtom.
Each ml contains 0.05 mg entecavir. 
En mililiter peroralne raztopine vsebuje 0,05 mg entekavirja.
Lactose monohydrate Magnesium stearate Cellulose, Microcrystalline Povidone 
Baraclude 1 mg filmsko obložene tablete Jedro tablete: krospovidon laktoza monohidrat magnezijev stearat mikrokristalna celuloza povidon
Methylhydroxybenzoate (E218) Propylhydroxybenzoate (E216) Orange flavour (acacia and natural flavours) Sodium hydroxide to adjust pH to approximately 6 Hydrochloric acid to adjust pH to approximately 6 Purified water 
natrijev hidroksid za uravnanje pH na približno 6 klorovodikova kislina za uravnanje pH na približno 6 prečiščena voda
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING 
POSEBNA NAVODILA ZA SHRANJEVANJE Pakiranje v pretisnem omotu:
Pre-existing lamivudine-resistant HBV is associated with an increased risk for subsequent entecavir resistance regardless of the degree of liver disease; in patients with decompensated liver disease, virologic breakthrough may be associated with serious clinical complications of the underlying liver disease. 
Pri bolnikih z dekompenzirano boleznijo jeter je povečanje virusnega bremena lahko povezano z resnimi kliničnimi zapleti osnovne bolezni jeter.
EU/1/06/343/003 30 x 1 film-coated tablet EU/1/06/343/006 90 x 1 film-coated tablet 
EU/1/06/343/006 90 x 1 filmsko obložena tableta
Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated liver disease, none had ALT elevations both > 10 times ULN and > 2 times baseline, and 1% of patients had ALT elevations > 2 times baseline together with total bilirubin > 2 times ULN and > 2 
Odstopanja od normalnih vrednosti laboratorijskih preiskav: med 48-tedenskim zdravljenjem pri nobenem od bolnikov, ki so prejemali entekavir, niso poročali o zvišanju vrednosti ALT, ki bi bile več kot 10 krat večje od zgornje meje normalne vrednosti (ULN; “upper limit of normal”) in sočasno več kot 2 krat večje od izhodiščnih vrednosti.
Bristol-Myers Squibb Pharma EEIG 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Bristol-Myers Squibb Pharma EEIG
EU/1/06/343/004 30 x 1 film-coated tablet EU/1/06/343/007 90 x 1 film-coated tablet 
EU/1/06/343/007 90 x 1 filmsko obložena tableta
In clinical studies with lamivudine-refractory patients, 4% had ALT elevations > 3 times baseline, and < 1% had ALT elevations > 2 times baseline together with total bilirubin > 2 times ULN and > 2 times baseline. 
Pri < 1% bolnikov so bile vrednosti ALT > 2 krat večje od izhodiščnih vrednosti in sočasno povečane tudi vrednosti skupnega bilirubina, ki so bile > 2 krat večje od ULN in > 2 krat večje od izhodiščnih vrednosti.
Sodium citrate 
Kreatininski očistek
Experience in lamivudine-refractory patients with compensated liver disease: In a randomised, double-blind study in HBeAg positive lamivudine-refractory patients (026), with 85% of patients presenting LVDr mutations at baseline, patients receiving lamivudine at study entry either switched to entecavir 1 mg once daily, with neither a washout nor an overlap period (n = 141), or continued on lamivudine 100 mg once daily (n = 145). 
Bolniki so do vključitve v študijo prejemali lamivudin, nato pa so bodisi začeli jemati entekavir v odmerku 1 mg na dan (brez obdobja prekinitve jemanja lamivudina in brez obdobja sočasnega jemanja z lamivudinom) (n = 141) ali pa nadaljevali z jemanjem lamivudina v odmerku 100 mg enkrat na dan (n = 145).
0.05 mg once daily* OR 0.5 mg every 5-7 days 
0,05 mg enkrat na dan* ALI
The Baraclude oral solution is recommended for patients weighing from 10 kg to 32.5 kg.Children weighing at least 32.6 kg may take the oral solution or the 0.5 mg tablet. 
Otroci s telesno maso vsaj 32,6 kg lahko jemljejo peroralno raztopino ali 0,5 mg tablete.
If you take more Baraclude than you should 
Če ste vzeli večji odmerek zdravila Baraclude, kot bi smeli Nemudoma se posvetujte s svojim zdravnikom.
Baraclude dosage 
Odmerjanje* zdravila Baraclude
Contents of the pack and other information What Baraclude contains 
Shranjevanje zdravila Baraclude Vsebina pakiranja in dodatne informacije
Baraclude 1 mg film-coated tablets Tablet core: 
Baraclude 1 mg filmsko obložene tablete
0.15 mg once daily* OR 0.5 mg every 72 hours 
0,15 mg enkrat na dan* ALI
The volume of distribution is around 10 L/kg. 
Volumen porazdelitve je okoli 10 l/kg.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22 April 2013 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 22. april 2013
This includes medicines obtained without a prescription. 
To velja tudi za zdravila, pridobljena brez recepta.
To benefit from your medicine you should take it regularly every day at the same time of the day. 
Da bi vam zdravilo koristilo, ga morate jemati redno vsak dan ob istem času.
2Isolated cases reported in post-marketing experience. 
2Osamljeni primeri, o katerih so poročali v okviru postmarketinških izkušenj.
In case of signs and symptoms of general central nervous system (CNS) overstimulation, careful symptomatic clinical treatment should be considered. 
Pri znakih in simptomih splošne prekomerne stimulacije osrednjega živčnega sistema (OŽS) je treba razmisliti o previdnem simptomatičnem kliničnem zdravljenju.
(≥1/10), common (≥1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥1/10,000 to <1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). 
(≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom ali s farmacevtom, preden vzamete to zdravilo.
• if you are allergic to memantine hydrochloride or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na memantinijev klorid ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
If you forget to take Memantine LEK - If you find you have forgotten to take your dose of Memantine LEK, wait and take your next dose at the usual time. 
Če ste pozabili vzeti zdravilo Memantin LEK - Če ste ugotovili, da ste pozabili vzeti predpisani odmerek zdravila Memantin LEK, počakajte in vzemite naslednji odmerek ob običajnem času.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IFAPPROPRIATE 
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Verovškova 57, 1526 Ljubljana Slovenia 
Verovškova 57, 1526 Ljubljana Slovenija
The tablet can be divided into equal doses. 
Tableta se lahko deli na enaki polovici.
Memantine LEK is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy. 
Zdravilo Memantin LEK ni priporočljivo uporabljati pri otrocih in mladostnikih mlajših od 18 let, zaradi pomanjkanja podatkov glede varnosti in učinkovitosti.
1Hallucinations have mainly been observed in patients with severe Alzheimer's disease. 
1Halucinacije so bile večinoma opažene pri bolnikih s hudo Alzheimerjevo boleznijo.
Memantine has an absolute bioavailability of approximately 100%. 
Absorpcija: Memantin ima absolutno biološko uporabnost okoli 100 %.
Pharmacotherapeutic group: Psychoanaleptics; Other Anti-dementia drugs, ATC code: N06DX01. 
Farmakoterapevtska skupina: psihoanaleptiki; druga zdravila za zdravljenje demence, oznaka ATC: N06DX01.
Adverse reactions are ranked according to system organ class, using the following convention: very common 
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti
• In post-marketing experience, isolated cases with international normalized ratio (INR) increases have been reported in patients concomitantly treated with warfarin. 
• V okviru postmarketinških izkušenj so poročali o osamljenih primerih povečanja mednarodno umerjenega razmerja (INR) pri bolnikih, ki so bili sočasno zdravljeni z varfarinom.
Very Rare (may affect up to 1 in 10,000 people): • Seizures 
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): • epileptični napadi
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Vendar pa mora imetnik dovoljenja za promet za to zdravilo predložiti redno posodobljena poročila o varnosti zdravila, če je zdravilo vključeno v seznam referenčnih datumov Unije (seznam EURD), opredeljen v členu 107c(7) Direktive 2001/83/ES in objavljen na evropskem spletnem portalu o zdravilih.
Relative large overdoses (200 mg and 105 mg/day for 3 days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms. 
Simptomi: Sorazmerno veliko preveliko odmerjanje (200 mg dnevno oziroma 105 mg dnevno, tri dni) je bilo povezano bodisi samo s simptomi utrujenosti, šibkosti in/ali driske bodisi je bilo brez simptomov.
In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 mL/min/1.73 m² and part of total renal clearance is achieved by tubular secretion. 
Pri prostovoljcih z normalnim delovanjem ledvic je celoten očistek (Cltot) 170 ml/min/1,73 m²; del celotnega ledvičnega očistka je dosežen s pomočjo tubularne sekrecije.
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine. 
Obvestite svojega zdravnika, če ste pred kratkim spremenili ali če nameravate bistveno spremeniti prehrano (npr. če preidete iz običajne hrane na strogo vegetarijansko prehrano), ali če imate ledvično tubularno acidozo (preveliko količino kislih spojin v krvi zaradi renalne disfunkcije (slabega delovanja ledvic)) ali če ste zboleli zaradi hudega vnetja sečil (strukture po kateri se prenaša seč).
In the most extreme case of overdose, the patient survived the oral intake of a total of 2,000 mg memantine with effects on the central nervous system (coma for 10 days, and later diplopia and agitation). 
V najekstremnejšem primeru prevelikega odmerjanja je bolnik preživel peroralni vnos 2000 mg memantina z učinki na osrednji živčni sistem (desetdnevna koma, kasneje diplopija in vznemirjenost).
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
A. IZDELOVALCI ODGOVORNI ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA
Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to 100 hours. 
Izločanje: Memantin se izloča na monoekspotencialni način s končnim razpolovnim časom (t½) 60 do 100 ur.
• There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is coadministered with HCT or any combination with HCT. 
• Obstaja možnost zmanjšane serumske koncentracije hidroklorotiazida (HCT) ob sočasni uporabi memantina in HCT oziroma kakršnikoli kombinaciji s HCT.
The score line is not intended for breaking the tablet. 
Razdelilna zareza ni namenjena delitvi tablete.
The most frequently occurring adverse reactions with a higher incidence in the memantine group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%). 
kot pri skupini, ki je prejemala placebo, so bili omotica (6,3 % proti 5,6 %), glavobol (5,2 % proti 3,9 %), zaprtje (4,6 % proti 2,6 %), zaspanost (3,4 % proti 2,2 %) in hipertenzija (4,1 % proti 2,8 %).
Furthermore, Memantine LEK has minor or moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care. 
Prav tako ima zdravilo Memantin LEK majhen do zmerno velik vpliv na sposobnost vožnje in upravljanja s stroji, zato je potrebno bolnike opozoriti na posebno previdnost.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI ODGOVORNI ZA SPROŠČANJE SERIJ
Memantine did not inhibit CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, flavin-containing monooxygenase, epoxide hydrolase or sulphation in vitro. 
Memantin in vitro ni zaviral CYP 1A2, 2A6, 2C9, 2D6, 2E1, 3A, monooksigenaze, ki vsebuje flavin, epoksidne hidroksilaze ali sulfatacije.
Psychotic reactions2 
Neznane pogostnosti psihotične reakcije2
Treatment of adult patients with moderate to severe Alzheimer's disease. 
Zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
- If you take a large overdose of Memantine LEK, contact your doctor or get medical advice, as you may need medical attention. 
- V primeru, da ste zaužili prevelik odmerek zdravila Memantin LEK, obvestite svojega zdravnika, ker boste morda potrebovali zdravniško obravnavo.
Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg. 
Linearnost: Študije na zdravih prostovoljcih so pokazale, da ima memantin linearno farmakokinetiko v razponu odmerkov od 10 do 40 mg.
Both active substances are chemically related NMDA-antagonists. 
Obe zdravilne učinkovine sta kemijsko sorodna antagonista NMDA.
In patients with mild or moderate hepatic impaired function (Child-Pugh A and Child-Pugh B), no dose adjustment is needed. 
Jetrna okvara: Pri bolnikih z blago ali zmerno jetrno okvaro (Child-Pugh A in Child-Pugh B) prilagoditev odmerka ni potrebna.
If you go into hospital, let your doctor know that you are taking Memantine LEK. 
V primeru, da ste sprejeti v bolnišnico, obvestite zdravnika, da jemljete zdravilo Memantin LEK.
Children and adolescents Memantine LEK is not recommended for children and adolescents under the age of 18 years. 
Zdravila Mamantin LEK ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
The recommended maintenance dose is 20 mg per day. 
Priporočeni vzdrževalni odmerek je 20 mg na dan.
Memantine LEK belongs to a group of medicines known as anti-dementia medicines. 
Zdravilo Memantin LEK sodi v skupino zdravil, znanih kot zdravila za zdravljenje demence.
In a clinical study in young healthy subjects, no relevant effect of memantine on the pharmacokinetics of galantamine was observed. 
V klinični raziskavi pri mladih zdravih prostovoljcih ni bilo opaziti pomembnega vpliva memantina na farmakokinetiko galantamina.
What is Memantine LEK used for Memantine LEK is used for the treatment of adult patients with moderate to severe Alzheimer's disease. 
Za kaj uporabljamo zdravilo Memantin LEK Zdravilo Memantin LEK uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Somnolence Confusion Hallucinations1 
Občasni halucinacije1
Other medicines and Memantine LEK 
Druga zdravila in zdravilo Memantin LEK
You may experience increased symptoms as described in section 4 “Possible side effects”. 
Morda boste občutili bolj izražene znake, ki so opisani v poglavju 4.
Memantine LEK belongs to a group of medicines called NMDA-receptor antagonists. 
Zdravilo Memantin LEK spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.
The usual starting dose is half a tablet of 10 mg once a day (1x 5 mg) for the first week. 
Običajni začetni odmerek je polovica 10 mg tablete enkrat dnevno (1 x 5 mg) v prvem tednu.
Concomitant administration of memantine with the antispasmodic medicinal products, dantrolene or baclofen, can modify their effects and a dose adjustment may be necessary. 
Sočasno dajanje memantina in spazmolitikov zdravili, dantrolena ali baklofena lahko spremeni njihove učinke, zato je morda potrebno prilagoditi odmerke.
Sambrook Pharmaceuticals Med SA 800 110 0333 (χωρίς χρέωση) / +30-210 
Sambrook Pharmaceuticals Med SA 800 110 0333 (toll free) / +30-210-8194280
• if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure). 
- če ste v preteklosti imeli epileptične napade, - če ste pred kratkim preboleli srčni infarkt (srčna kap), imate kongestivno srčno odpoved ali neurejeno hipertenzijo (visok krvni tlak).
In the event of overdose, treatment should be symptomatic. 
Zdravljenje: Pri prevelikem odmerjanju je potrebno simptomatično zdravljenje.
How to store Memantine LEK Contents of the pack and other information 
Shranjevanje zdravila Memantin LEK Vsebina pakiranja in dodatne informacije
Constipation Vomiting Pancreatitis2 
Neznane pogostnosti pankreatitis2
amantadine, ketamine, dextromethorphan dantrolene, baclofen cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine hydrochlorothiazide (or any combination with hydrochlorothiazide) anticholinergics (substances generally used to treat movement disorders or intestinal cramps) anticonvulsants (substances used to prevent and relieve seizures) barbiturates (substances generally used to induce sleep) dopaminergic agonists (substances such as L-dopa, bromocriptine) neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants 
amantadin, ketamin, dekstrometorfan dantrolen, baklofen cimetidin, ranitidin, prokainamid, kinidin, kinin, nikotin hidroklorotiazid (ali kombinacije zdravil, ki vsebujejo hidroklorotiazid) antiholinergiki (zdravila, ki se na splošno uporabljajo za zdravljenje motenj gibanja in trebušnih krčev)
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Podrobni podatki o tem izdelku so na voljo na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu.
In post-marketing experience these reactions have been reported in patients treated with memantine. 
Po začetku trženja zdravila so te dogodke navajali pri bolnikih, zdravljenih z memantinom.
What Memantine LEK is and what it is used for What you need to know before you take Memantine LEK How to take Memantine LEK Possible side effects 
Kaj je zdravilo Memantin LEK in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Memantin LEK Kako jemati zdravilo Memantin LEK
In particular, Memantine LEK may change the effects of the following medicines and their dose may need to be adjusted by your doctor: 
Posebno v primeru, da skupaj z zdravilom Memantin LEK jemljete naslednja zdravila, se učinki le teh lahko spremenijo in bo morda vaš zdravnik moral prilagoditi odmerek:
The use of medicinal products called amantadine (for the treatment of Parkinson's disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided. 
Potrebno se je izogibati sočasni uporabi zdravil, kot so amantadin (za zdravljenje Parkinsonove bolezni), ketamin (snov, ki se uprablja kot anestetik), dekstrometorfan (splošna uporaba pri zdravljenju kašlja) in ostali zaviralci receptorjev NMDA.
In patients with severe renal impairment (creatinine clearance 5 - 29 mL/min) daily dose should be 10 mg per day. 
Pri bolnikih s hudo okvaro delovanja ledvic (očistek kreatinina 5 - 29 ml/min) naj bo dnevni odmerek 10 mg.
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4-and 6-hydroxy-memantine, and 1-nitroso-3,5-dimethyl-adamantane. 
Pri človeku so poglavitni metaboliti N-3,5-dimetil-gludantan, izomerna mešanica 4- in 6-hidroksi-memantina in 1